For over a century, cancer has been classified largely on the basis of cellular differentiation. Despite an onslaught of genomic data that threatened to replace this system, classification by cell type has only become stronger. We now know that differentiation programs dramatically alter the genomic landscape in which cancers form, grow, and spread. It follows that differentiation programs have major clinical implications. This presentation will discuss our laboratory’s investigations into differentiation programs in prostate and bladder cancer, along with their implications for translational research and surgical pathology, and clinical care.

Recent publications by Dr. Stegmaier:


